Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Hurt

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Open Forum Infectious Diseases|April 6, 2019
Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter StudyH Nina Kim, Robin M Nance, Jessica S Williams-Nguyen, et al.
The Journal of Infectious Diseases|November 8, 2025
Estimation of prevention-effective CAB-LA concentrations among men who have sex with men (MSM) and transgender women (TGW) in HPTN 083Brett Hanscom, Mark A Marzinke, Xinnong Li, et al.
Harm Reduction Journal|November 29, 2024
Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communitiesAngela T Estadt, David Kline, William C Miller, et al.
AIDS Research and Human Retroviruses|April 7, 2017
Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United StatesIris Chen, Yinfeng Zhang, Vanessa Cummings, et al.
American Journal of Epidemiology|November 13, 2019
Association Between Chronic Hepatitis C Virus Infection and Myocardial Infarction Among People Living With HIV in the United StatesJessica Williams-Nguyen, Stephen E Hawes, Robin M Nance, et al.
Open Forum Infectious Diseases|February 3, 2025
Prevalence and Correlates of Hepatitis C Viremia Among People With Human Immunodeficiency Virus in the Direct-Acting Antiviral EraJimmy Ma, Robin M Nance, Edward Cachay, et al.
The Lancet. Infectious Diseases|July 8, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trialGary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al.
BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Open Forum Infectious Diseases|April 6, 2019
Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter StudyH Nina Kim, Robin M Nance, Jessica S Williams-Nguyen, et al.
The Journal of Infectious Diseases|November 8, 2025
Estimation of prevention-effective CAB-LA concentrations among men who have sex with men (MSM) and transgender women (TGW) in HPTN 083Brett Hanscom, Mark A Marzinke, Xinnong Li, et al.
Harm Reduction Journal|November 29, 2024
Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communitiesAngela T Estadt, David Kline, William C Miller, et al.
AIDS Research and Human Retroviruses|April 7, 2017
Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United StatesIris Chen, Yinfeng Zhang, Vanessa Cummings, et al.
American Journal of Epidemiology|November 13, 2019
Association Between Chronic Hepatitis C Virus Infection and Myocardial Infarction Among People Living With HIV in the United StatesJessica Williams-Nguyen, Stephen E Hawes, Robin M Nance, et al.
Open Forum Infectious Diseases|February 3, 2025
Prevalence and Correlates of Hepatitis C Viremia Among People With Human Immunodeficiency Virus in the Direct-Acting Antiviral EraJimmy Ma, Robin M Nance, Edward Cachay, et al.
The Lancet. Infectious Diseases|July 8, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trialGary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al.
BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.
Pageof 8